Document:USA FDA Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs β Improving Human Subject Protection Jan-2009: Difference between revisions
From GxPlex
Gxplex admin (talk | contribs) m 1 revision imported |
Remove static References table, superseded by live #ask in Template:DocumentData (GxPlexBot) Β |
||
| (8 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
{{DocumentData | |||
Β | |||
|reference=USAΒ FDA Guidance for Clinical | |reference=USAΒ FDA Guidance for Clinical | ||
Investigators, | Investigators, | ||
| Line 47: | Line 23: | ||
|contributors= | |contributors= | ||
}} | }} | ||
Latest revision as of 14:15, 16 July 2026
| Document information | |
|---|---|
| Reference | USA FDA Guidance for Clinical
Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs β Improving Human Subject Protection Jan-2009 |
| Validity area | USA |
| Scope(s) | G |
| Document name | FDA Guidance for Clinical
Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs β Improving Human Subject Protection |
| Version / Revision | Jan-2009 |
| Status | Superseded / Invalid |
| Document type | Official recommendation |
| Language(s) | EN |
| Description | Guidance for Clinical Investigators, Sponsors, and IRBs
Adverse Event Reporting to IRBs β Improving Human Subject Protection |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
References
| Scope | Document part | Language | Preview | |
|---|---|---|---|---|
| USA FDA Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs β Improving Human Subject Protection Jan-2009 III A. ; IV. | G | III A. ; IV. | EN | [...]
III. REPORTING AEs TO IRBs IN CLINICAL TRIALS OF DRUG AND BIOLOGICAL PRODUCTS CONDUCTED UNDER IND REGULATIONS A. How to Determine If an AE is an⦠|
| USA FDA Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs β Improving Human Subject Protection Jan-2009 Introduction ; III. B. ; Evaluation | G | Introduction ; III. B. ; Evaluation | EN | [...] For clinical investigations of drug and biological products conducted under an investigational new drug (IND) application, information about advβ¦ |
| USA FDA Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs β Improving Human Subject Protection Jan-2009 Introduction ; III. B. ; IV. | G | Introduction ; III. B. ; IV. | EN | [...] For clinical investigations of drug and biological products conducted under an investigational new drug (IND) application, information about advβ¦ |
